Envestnet Asset Management
PRME icon

Envestnet Asset Management’s Prime Medicine PRME Stock Holding History

Envestnet Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Sell
28,278
-762
-3% -$2.53K ﹤0.01% 4750
2026
Q1 		$101K Sell
29,040
-3,536
-11% -$13.5K ﹤0.01% 4624
2025
Q4 		$113K Buy
+32,576
New +$145K ﹤0.01% 4356
2025
Q2 		– Sell
-23,515
Closed -$46.8K – 4531
2025
Q1 		$46.8K Buy
23,515
+1,958
+9% +$5K ﹤0.01% 4298
2024
Q4 		$62.9K Sell
21,557
-6,798
-24% -$23.9K ﹤0.01% 4251
2024
Q3 		$110K Buy
28,355
+6,695
+31% +$31K ﹤0.01% 4126
2024
Q2 		$111K Sell
21,660
-1,220
-5% -$7.4K ﹤0.01% 4042
2024
Q1 		$160K Buy
22,880
+510
+2% +$3.87K ﹤0.01% 3992
2023
Q4 		$198K Buy
22,370
+5,754
+35% +$44.3K ﹤0.01% 3830
2023
Q3 		$159K Buy
+16,616
New +$216K ﹤0.01% 3783

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Envestnet Asset Management's PRME Position: Q2 2026 in Review

Envestnet Asset Management reduced its Prime Medicine (PRME) stake by 2.6% in Q2 2026, selling an estimated $2.53K and leaving 28,278 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4750.

Envestnet Asset Management first reported a position in PRME in Q3 2023 and has held it in 10 quarters since. The position peaked at $198K in Q4 2023. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Envestnet Asset Management held 28,278 shares of Prime Medicine worth $104K as of Q2 2026.
  • Envestnet Asset Management sold 762 Prime Medicine shares in Q2 2026, an estimated $2.53K.
  • Prime Medicine made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4750 holding.
  • Envestnet Asset Management first reported a position in Prime Medicine in Q3 2023 and has held it in 10 quarters since.
  • Envestnet Asset Management's Prime Medicine position peaked at $198K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.